Stocks News

LAST PRICE
76.9700
TODAY'S CHANGE (%)
Trending Up1.1000 (1.4498%)

Bid / Lots
69.0200/ 1
Ask / Lots
70.0000/ 1
Open / Previous Close
75.8900 / 75.8700
Day Range
Low 75.4236
High 77.0100
52 Week Range
Low 50.3498
High 83.9500
Volume
1,843,584
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: INCY
  
  Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
  WILMINGTON, Del.--(BUSINESS WIRE)--November 18, 2024--
  Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings.
Nov 14, 2024
- DJ Incyte Is Maintained at Sector Perform by RBC Capital, from 12:17PM ET on Thursday Nov 14, 2024 by Dow Jones
  12:17PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: INCY
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/INCY/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 12:17 ET (17:17 GMT)
- Incyte to Present at Upcoming Investor Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: INCY
  
  Incyte to Present at Upcoming Investor Conference
  WILMINGTON, Del.--(BUSINESS WIRE)--November 14, 2024--
  Incyte (Nasdaq: INCY) announced today that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami.
- RBC Raises Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating, from 7:16AM ET on Thursday Nov 14, 2024 by MT Newswires
  7:16AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: INCY
  07:16 AM EST, 11/14/2024 (MT Newswires) -- Incyte (INCY) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $52 to $97. (MT Newswires covers equity, commodity and economic research fro...
- RBC Capital Adjusts Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating, from 7:01AM ET on Thursday Nov 14, 2024 by MT Newswires
  7:01AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: INCY
  07:01 AM EST, 11/14/2024 (MT Newswires) -- Incyte (INCY) has an average rating of outperform and price targets ranging from $52 to $97, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from maj...

Nov 16, 2024
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by PR Newswire
  10:45AM ET on Saturday Nov 16, 2024 by PR Newswire
  Companies Mentioned: BMRN
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
  10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
  Companies Mentioned: BMRN
Nov 15, 2024
- Wolfe Research Initiates BioMarin Pharmaceutical at Outperform With $95 Price Target, from 7:22AM ET on Friday Nov 15, 2024 by MT Newswires
  7:22AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: BMRN
- DJ BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research, from 5:26AM ET on Friday Nov 15, 2024 by Dow Jones
  5:26AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: BMRN
Nov 14, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $350,324, According to a Recent SEC Filing, from 2:47PM ET on Thursday Nov 14, 2024 by MT Newswires
  2:47PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: BMRN
Nov 13, 2024
- Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing, from 6:29PM ET on Wednesday Nov 13, 2024 by MT Newswires
  6:29PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: EXAS
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy, from 1:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
  1:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: EXAS
Nov 12, 2024
- Charles River Laboratories International Insider Sold Shares Worth $1,647,418, According to a Recent SEC Filing, from 4:44PM ET on Tuesday Nov 12, 2024 by MT Newswires
  4:44PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: CRL
Nov 11, 2024
- DJ Charles River Labs Is Maintained at Hold by TD Cowen, from 11:00AM ET on Monday Nov 11, 2024 by Dow Jones
  11:00AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: CRL
- TD Cowen Adjusts Price Target on Charles River Laboratories International to $227 From $203, Maintains Hold Rating, from 9:46AM ET on Monday Nov 11, 2024 by MT Newswires
  9:46AM ET on Monday Nov 11, 2024 by MT Newswires
  Companies Mentioned: CRL

Incyte Corp
NASDAQ:INCYUnited States

Search Criteria

Yesterday

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs, from 8 hours ago by Dow Jones

Nov 14, 2024

DJ Incyte Is Maintained at Sector Perform by RBC Capital, from 12:17PM ET on Thursday Nov 14, 2024 by Dow Jones

Incyte to Present at Upcoming Investor Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

RBC Raises Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating, from 7:16AM ET on Thursday Nov 14, 2024 by MT Newswires

RBC Capital Adjusts Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating, from 7:01AM ET on Thursday Nov 14, 2024 by MT Newswires

Peers Headlines

Nov 16, 2024

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by PR Newswire

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by Dow Jones

Nov 15, 2024

Wolfe Research Initiates BioMarin Pharmaceutical at Outperform With $95 Price Target, from 7:22AM ET on Friday Nov 15, 2024 by MT Newswires

DJ BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research, from 5:26AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $350,324, According to a Recent SEC Filing, from 2:47PM ET on Thursday Nov 14, 2024 by MT Newswires

Nov 13, 2024

Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing, from 6:29PM ET on Wednesday Nov 13, 2024 by MT Newswires

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy, from 1:00PM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Charles River Laboratories International Insider Sold Shares Worth $1,647,418, According to a Recent SEC Filing, from 4:44PM ET on Tuesday Nov 12, 2024 by MT Newswires

Nov 11, 2024

DJ Charles River Labs Is Maintained at Hold by TD Cowen, from 11:00AM ET on Monday Nov 11, 2024 by Dow Jones

TD Cowen Adjusts Price Target on Charles River Laboratories International to $227 From $203, Maintains Hold Rating, from 9:46AM ET on Monday Nov 11, 2024 by MT Newswires